

Supplementary data

Table S1: BMSC donor information marker expression.

Donor ID	1	2	3	4	5	6	7	8
Sex	Male	Female	Female	Male	Male	-	-	Female
Age	90	87	91	92	82	-	-	56
BMI	24.2	28.9	23.4	19.0	25.6	-	-	48.4

- donor information unknown

Table S2: BMSC surface marker expression.

Donor	1	2	3	4	5	6	7	8
Passage	2	2	3	3	3	3	2	3
CD14	1.2 %	2.1 %	7.4 %	4.1 %	5.2 %	2.6 %	3.4 %	1.7 %
CD19	1.2 %	2.4 %	7.1 %	2.5 %	2.0 %	1.1 %	5.3 %	1.6 %
CD34	0.8 %	0.5 %	3.1 %	2.1 %	1.0 %	0.4 %	1.4 %	1.5 %
CD45	1.6 %	1.0 %	8.8 %	6.2 %	3.5 %	0.9 %	2.7 %	2.4 %
CD73	100.0 %	100.0 %	95.4 %	95.6 %	95.6 %	100.0 %	100.0 %	100.0 %
CD90	98.0 %	89.4 %	90.2 %	94.2 %	86.6 %	88.0 %	97.6 %	99.8 %
CD105	100.0 %	99.9 %	93.6 %	98.7 %	97.2 %	100.0 %	100.0 %	99.9 %
HLA-DR	97.1 %	88.7 %	92.2 %	88.6 %	96.8 %	95.7 %	72.0 %	96.0 %

Table S3: Antibodies used in immunocytochemical staining.

<i>Osteogenically differentiated BMSCs</i>				
Type	Antibody	Host species	Clone	Dilution
Primary	Anti-Collagen I (ab260043) ¹	Rabbit	EPR22894-89	1:250
Primary	Anti-Osteocalcin (MAB1419) ²	Mouse	IgG1 Clone #190125	1 : 50
Secondary	Anti-rabbit IgG Alexa fluor 488 (A21206) ³	Donkey		1 : 500
Secondary	Anti-mouse IgG1 Alexa fluor 488 (A21121) ³	Goat		1 : 500
<i>Angiogenesis assay</i>				
Type	Antibody	Host species	Clone	Dilution
Primary	Anti- α -smooth muscle actin (ab7817) ¹	Mouse	1A4	
Secondary	Anti-mouse IgG (H+L) Alexa Fluor 568 (A11031) ³	Goat		1:500

1 Abcam, Cambridge, United Kingdom. 2 R&D systems, Minneapolis, MN, US. 4 Sigma-Aldrich., 3 Thermo Fisher Scientific




Figure S1: Secondary antibody control images showing an insignificant amount of background staining by the secondary antibodies in absence of any primary antibody. BM = basic medium, OM = osteogenic medium. Scale bar: 200µm.

Table S4: Primer sequences for qRT-PCR.

Gene	Accession number	5'-Sequence-3'	Product size (bp)
<i>DLX5</i>	NM_005221.5	Forward ACCATCCGTCTCAGGAATCG Reverse CCCCCGTAGGGCTGTAGTAGT	75
<i>FABP4</i>	NM_001442	Forward GGTGGTGGGAATGCGTCATG Reverse CAACGTCCCTTGGCTTATGC	71
<i>LEP</i>	NM_000230	Forward ACAATTGTCACCAGGATCAATGAC Reverse TCCAAACCGGTGACTTTCTG	73
<i>RPLP0</i>	NM_001002	Forward AATCTCCAGGGGCACCATT Reverse CGCTGGCTCCCACCTTTGT	70
<i>RUNX2A</i>	NM_001024630.3	Forward CTTCATTCGCCTCACAAACAAC Reverse TCCTCCTGGAGAAAGTTTGCA	62
<i>SP7</i>	AF477981	Forward TGAGCTGGAGCGTCATGTG Reverse TCGGGTAAAGCGCTTGGA	79

bp: base pair




Figure S2: Representative image of Alizarin Red S stainings for the mineralized matrix from a culture well plate with osteogenically differentiated BMSC at 21 days of culture with drugs added at the indicated concentrations. melfl = melflufen, melph = melphalan, doxo = doxorubicin




Figure S3: Phase contrast images of osteogenically differentiated BMSCs at 21 days of culture.

BM = basic medium control, OM = osteogenic medium control without drugs. Scale bar:

500μm